Skip to main content

Advertisement

SpringerLink
Log in

Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768–3785. doi:10.1182/blood-2004-09-3502

    Article  PubMed  CAS  Google Scholar 

  2. Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, Olsen E, Kim YH, Dummer R, Pimpinelli N, Whittaker S, Hodak E, Cerroni L, Berti E, Horwitz S, Prince HM, Guitart J, Estrach T, Sanches JA, Duvic M, Ranki A, Dreno B, Ostheeren-Michaelis S, Knobler R, Wood G, Willemze R (2011) EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 118:4024–4035. doi:10.1182/blood-2011-05-351346

    Article  PubMed  CAS  Google Scholar 

  3. Fujita H, Nagatani T, Miyazawa M, Wada H, Koiwa K, Komatsu H, Ikezawa Z (2008) Primary cutaneous anaplastic large cell lymphoma successfully treated with low-dose oral methotrexate. Eur J Dermatol 18:360–361. doi:10.1684/ejd.2008.0420

    PubMed  Google Scholar 

  4. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH (2003) CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 49:1049–1058. doi:10.1016/S0190

    Article  PubMed  Google Scholar 

  5. Brice P, Cazals D, Mounier N, Verola O, Neidhart-Berard AM, Remenieras L, Deconinck E, Doyen C, Hamelsand J, Molina T, Moulonguet I, Gisselbrecht C (1998) Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. Leukemia 12:213–219

    Article  PubMed  CAS  Google Scholar 

  6. Katz J, Janik JE, Younes A (2011) Brentuximab vedotin (SGN-35). Clin Cancer Res 17:6428–6436. doi:10.1158/1078-0432.CCR-11-0488

    Article  PubMed  CAS  Google Scholar 

  7. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A (2012) Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. J Clin Oncol 30:2190–2196. doi:10.1200/JCO.2011.38.0402

    Article  PubMed  CAS  Google Scholar 

  8. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30:2183–2189. doi:10.1200/JCO.2011.38.0410

    Article  PubMed  CAS  Google Scholar 

  9. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821. doi:10.1056/NEJMoa1002965

    Article  PubMed  CAS  Google Scholar 

  10. Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL, Kim YH (2009) A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 15:6217–6224. doi:10.1158/1078-0432.CCR-09-0162

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of Interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Hematology–Oncology, Memorial Hospital of Rhode Island, 111 Brewster St, Pawtucket, RI, 02860, USA

    Amrita Desai & Adam J. Olszewski

  2. Department of Dermatology, Rhode Island Hospital, Providence, RI, USA

    Gladys H. Telang

  3. Alpert Medical School of Brown University, Providence, RI, USA

    Amrita Desai, Gladys H. Telang & Adam J. Olszewski

Authors
  1. Amrita Desai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gladys H. Telang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adam J. Olszewski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adam J. Olszewski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Desai, A., Telang, G.H. & Olszewski, A.J. Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin. Ann Hematol 92, 567–568 (2013). https://doi.org/10.1007/s00277-012-1610-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-012-1610-3

Keywords

Search

Navigation